Earlier this month, Goodwin Procter represented Thomas, McNerney & Partners in its $15 million Series A financing of InnoPharma, a Piscataway, NJ-based developer of niche generic and specialty pharmaceuticals. Thomas, McNerney & Partners is a healthcare venture firm that invests in life science and medical technology companies at all stages of development.
InnoPharma specializes in generics that may be difficult to develop for technical reasons, have a niche area of use or require complicated manufacturing support. The company develops these types of products in sterile dosage forms, and out-licenses them to pharmaceutical marketing companies for commercialization.
In InnoPharma’s release announcing the financing, Thomas, McNerney partner Alex Zisson said that they were attracted to InnoPharma because of the company’s impressive track record of FDA filings, approvals and partnerships. InnoPharma will use the funds to accelerate the development of its product pipeline.
“We’re very pleased to have helped Thomas, McNerney & Partners complete this investment,” said Mitch Bloom, a partner in and co-chair of Goodwin Procter’s Life Sciences Practice. “InnoPharma is a top-notch company and will be an excellent addition to their portfolio.”
Bloom led the Goodwin deal team.